BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Venetoclax: trial readouts and FDA decisions

3 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 6 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: AbbVie, Sellas Life Sciences Group, OncoVerity, Inc., Aptose Biosciences Inc., Genentech, Inc., Loxo Oncology, Inc., AB Science. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12-30 est.P1/P2Sellas Life Sciences Group SLSNCT04588922 Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AMLHematologic Malignanciesrecruiting160
2027-01 est.P2OncoVerity, Inc.NCT06384261 A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive TherapyLeukemia, Myeloid, Acuteactive not recruiting140
2027-02 est.P1/P2AbbVie ABBVNCT04086264 IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid LeukemiaAcute Myeloid Leukemiaactive not recruiting218

Readouts, last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11 est.P2AbbVie ABBVNCT04895436 Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring ChronicChronic Lymphocytic Leukemia (CLL)recruiting75
2026-11 est.P1/P2Aptose Biosciences Inc.NCT03850574 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory AcuteLeukemia, Myeloid, Acute; Refractory AML; Relapsed Adult AML; Myelodysplastic Syndrome With Excess Brecruiting240
2026-10-28P2Genentech, Inc.NCT06524375 A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Chronic Lymphocytic Leukemiaactive not recruiting118
2026-10 est.P3Loxo Oncology, Inc.NCT04965493 A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphomaactive not recruiting600
2026-08 est.P1/P2AB ScienceNCT05211570 AB8939 in Patients With Relapsed/Refractory Acute Myeloid LeukemiaAcute Myeloid Leukemia Refractory; Acute Myeloid Leukemia, in Relapse; Myelodysplastic Syndrome Acutrecruiting78
2026-08 est.P3AbbVie ABBVNCT03539744 A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in ParticiMultiple Myelomaactive not recruiting265

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.